These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34986768)

  • 1.
    Jose J; S S; Mathew B; Parambi DGT
    Comb Chem High Throughput Screen; 2022; 25(12):1991-2000. PubMed ID: 34986768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico trials: Verification, validation and uncertainty quantification of predictive models used in the regulatory evaluation of biomedical products.
    Viceconti M; Pappalardo F; Rodriguez B; Horner M; Bischoff J; Musuamba Tshinanu F
    Methods; 2021 Jan; 185():120-127. PubMed ID: 31991193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of advanced in silico methods for predictive modeling and information integration.
    Valerio LG
    Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):395-8. PubMed ID: 22432718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro-In Vivo Correlation Using In Silico Modeling of Physiological Properties, Metabolites, and Intestinal Metabolism.
    Choi SM; Kang CY; Lee BJ; Park JB
    Curr Drug Metab; 2017; 18(11):973-982. PubMed ID: 29086683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation.
    Jiang W; Kim S; Zhang X; Lionberger RA; Davit BM; Conner DP; Yu LX
    Int J Pharm; 2011 Oct; 418(2):151-60. PubMed ID: 21803144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality by design (QbD) approach in marketing authorization procedures of Non-Biological Complex Drugs: A critical evaluation.
    Zagalo DM; Sousa J; Simões S
    Eur J Pharm Biopharm; 2022 Sep; 178():1-24. PubMed ID: 35908664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory forum opinion piece*: supporting the need for international harmonization of safety assessments for food flavoring substances.
    Konishi Y; Hayashi SM; Fukushima S
    Toxicol Pathol; 2014 Aug; 42(6):949-53. PubMed ID: 23881932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model verification tools: a computational framework for verification assessment of mechanistic agent-based models.
    Russo G; Parasiliti Palumbo GA; Pennisi M; Pappalardo F
    BMC Bioinformatics; 2022 May; 22(Suppl 14):626. PubMed ID: 35590242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of modelling and simulation: a European regulatory perspective.
    Jönsson S; Henningsson A; Edholm M; Salmonson T
    Clin Pharmacokinet; 2012 Feb; 51(2):69-76. PubMed ID: 22257148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data Integrity-A Study of Current Regulatory Thinking and Action.
    Shafiei N; De Montardy R; Rivera-Martinez E
    PDA J Pharm Sci Technol; 2015; 69(6):762-70. PubMed ID: 26659106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety assessment of natural products in Malaysia: current practices, challenges, and new strategies.
    M Pauzi NA; Cheema MS; Ismail A; Ghazali AR; Abdullah R
    Rev Environ Health; 2022 Jun; 37(2):169-179. PubMed ID: 34582637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Provable Data Integrity in the Pharmaceutical Industry Based on Version Control Systems and the Blockchain.
    Steinwandter V; Herwig C
    PDA J Pharm Sci Technol; 2019; 73(4):373-390. PubMed ID: 30770485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and In silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: Comparison among various regulatory agencies.
    Kollipara S; Ahmed T; Bhattiprolu AK; Chachad S
    Biopharm Drug Dispos; 2021 Jul; 42(7):297-318. PubMed ID: 34019712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Credibility assessment of computational models according to ASME V&V40: Application to the Bologna Biomechanical Computed Tomography solution.
    Aldieri A; Curreli C; Szyszko JA; La Mattina AA; Viceconti M
    Comput Methods Programs Biomed; 2023 Oct; 240():107727. PubMed ID: 37523955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.